XFOR

4.24

2.53% -0.11

Handel nachbörslich: 4.24

X 4 Pharmaceuticals Inc (XFOR)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$4.35

Offen:

$4.23

24-Stunden-Volumen:

205.89K

Relative Volume:

0.44

Marktkapitalisierung:

$385.50M

Einnahmen:

$35.11M

Nettoeinkommen (Verlust:

$-79.20M

KGV:

-0.9777

EPS:

-4.3367

Netto-Cashflow:

$-88.62M

1W Leistung:

-1.62%

1M Leistung:

+24.71%

6M Leistung:

+21.84%

1J Leistung:

-38.01%

1-Tages-Spanne:

$4.17

$4.435

1-Wochen-Bereich:

$3.89

$4.47

52-Wochen-Spanne:

$1.35

$6.96

X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile

Firmenname

X 4 Pharmaceuticals Inc

Sektor

Healthcare (1118)

Branche

Biotechnology (624)

Telefon

857-529-8300

Adresse

61 NORTH BEACON STREET, BOSTON, MA

Mitarbeiter

Twitter

@x4pharma

Nächster Verdiensttermin

2026-03-24

Neueste SEC-Einreichungen

XFOR's Discussions on Twitter

Compare XFOR vs VRTX, REGN, ARGX, ALNY, INSM

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
XFOR X 4 Pharmaceuticals Inc	4.24	385.50M	35.11M	-79.20M	-88.62M	-4.3367
VRTX Vertex Pharmaceuticals Inc	438.71	111.45B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	761.85	80.54B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	746.42	46.32B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	318.85	42.29B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	162.43	35.01B	606.42M	-1.28B	-997.58M	-6.403

X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-09	Eingeleitet	Guggenheim	Buy
2025-12-05	Fortgesetzt	Stifel	Buy
2023-12-12	Herabstufung	B. Riley Securities	Buy → Neutral
2023-08-30	Fortgesetzt	B. Riley Securities	Buy
2022-12-22	Eingeleitet	Cantor Fitzgerald	Overweight
2022-12-12	Eingeleitet	Piper Sandler	Overweight
2019-12-23	Eingeleitet	Oppenheimer	Outperform
2019-12-18	Eingeleitet	ROTH Capital	Buy
2019-12-09	Hochstufung	Citigroup	Neutral → Buy
2019-12-05	Eingeleitet	B. Riley FBR	Buy
2019-06-07	Eingeleitet	Stifel	Buy
2019-06-05	Eingeleitet	Cowen	Outperform

Alle ansehen

X 4 Pharmaceuticals Inc Aktie (XFOR) Neueste Nachrichten

Apr 02, 2026

XFOR SEC FilingsX4 Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 02, 2026

Apr 01, 2026

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Apr 01, 2026

Mar 31, 2026

Stonepine Capital (QNRX) files Form 4 as 10% owner with no trades - Stock Titan

Mar 31, 2026

Is ANIP Undervalued? How to Read Its 9.3x Forward P/E - TradingView

Mar 31, 2026

Tech Rally: What analysts say about X4 Pharmaceuticals Inc stock2026 Buyback Activity & Safe Capital Investment Plans - baoquankhu1.vn

Mar 31, 2026

Mar 30, 2026

Is X4 Pharmaceuticals Inc impacted by rising ratesWeekly Earnings Recap & Intraday High Probability Setup Alerts - baoquankhu1.vn

Mar 30, 2026

Mar 29, 2026

Performance Recap: How does X4 Pharmaceuticals Inc score in quality rankings2026 PreEarnings & Weekly High Conviction Trade Ideas - baoquankhu1.vn

Mar 29, 2026

Mar 27, 2026

Venrock funds trim KalVista (KALV) stake, retain 5.09M shares - Stock Titan

Mar 27, 2026

Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Global X Japan Co. Ltd. - MarketBeat

Mar 27, 2026

Mar 26, 2026

Layoff Tracker: Takeda Restructuring Will Affect Workforce, Could Include Layoffs - BioSpace

Mar 26, 2026

Mar 25, 2026

Earnings Risk: How correlated is X4 Pharmaceuticals Inc to the S P5002026 Investor Takeaways & Fast Gain Swing Alerts - baoquankhu1.vn

Mar 25, 2026

XFOR|X4 Pharmaceuticals Inc|Price:4.090|Chg%:0.27 - TradingKey

Mar 25, 2026

[Form 4] RECURSION PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan

Mar 25, 2026

Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML) - Business Wire

Mar 25, 2026

Mar 24, 2026

Tarsus Pharmaceuticals (TARS) COO sells 2,989 shares in planned trade - Stock Titan

Mar 24, 2026

FDA flags misleading claims for cancer drug by biotech billionaire Patrick Soon-Shiong - WHEC.com

Mar 24, 2026

Mar 23, 2026

Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review - Business Wire

Mar 23, 2026

Mar 22, 2026

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Mar 22, 2026

Mar 21, 2026

If You Invested $1,000 in X4 Pharmaceuticals Inc (XFOR) - Stock Titan

Mar 21, 2026

X4 Pharmaceuticals, Inc.: Fundamental Analysis and Financial Ratings | | US98420X2027 - marketscreener.com

Mar 21, 2026

X4 Pharmaceuticals (NASDAQ:XFOR) Raised to Hold at Wall Street Zen - MarketBeat

Mar 21, 2026

Mar 20, 2026

PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide) - PR Newswire

Mar 20, 2026

X4 Pharmaceuticals (NASDAQ: XFOR) seeks approval for equity plan and pay at 2026 meeting - Stock Titan

Mar 20, 2026

Q3 Earnings Forecast for XFOR Issued By Brookline Cap M - MarketBeat

Mar 20, 2026

Mar 19, 2026

Tarsus (NASDAQ: TARS) HR chief sells 12,274 shares in tax-related trades - Stock Titan

Mar 19, 2026

Tax-driven stock sale by Tarsus (TARS) chief commercial officer - Stock Titan

Mar 19, 2026

Children’s ibuprofen sold nationwide recalled by FDA - FOX8 WGHP

Mar 19, 2026

Analysts’ Top Healthcare Picks: X4 Pharmaceuticals (XFOR), Boston Scientific (BSX) - The Globe and Mail

Mar 19, 2026

Research Analysts Set Expectations for XFOR Q1 Earnings - MarketBeat

Mar 19, 2026

Mar 18, 2026

Crinetics Pharmaceuticals (CRNX) COO sells 9,911 shares for RSU taxes - Stock Titan

Mar 18, 2026

Crinetics (NASDAQ: CRNX) CSO sells shares to cover RSU tax - Stock Titan

Mar 18, 2026

RA Capital entities boost Acumen (NASDAQ: ABOS) stake with 6.1M-share grant - Stock Titan

Mar 18, 2026

X4 Pharmaceuticals, Inc. 2025 Annual Report: Business Overview, Regulatory Compliance, and Risk Factors - Minichart

Mar 17, 2026

X4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance

Mar 17, 2026

XFOR: 4WARD Phase 3 trial progresses, EMA backs mavorixafor, and cash runway extends to 2028 - TradingView

Mar 17, 2026

X4 Pharmaceuticals: Q4 Earnings Snapshot - 10tv.com

Mar 17, 2026

EMA panel backs first WHIM syndrome drug as X4 secures cash to 2028 - Stock Titan

Mar 17, 2026

X4 Pharmaceuticals 2025 10-K: $35.1M Revenue, $(79.2)M Net Loss - TradingView

Mar 17, 2026

XFOR: 2025 revenue surged to $35.1M, but net loss increased to $79.2M amid restructuring and R&D focus - TradingView

Mar 17, 2026

X4 Pharmaceuticals (NASDAQ: XFOR) cuts costs, raises cash to advance mavorixafor - Stock Titan

Mar 17, 2026

X4 Pharmaceuticals (XFOR) Projected to Post Quarterly Earnings on Tuesday - MarketBeat

Mar 17, 2026

Mar 16, 2026

X4 Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com

Mar 16, 2026

Amneal Pharmaceuticals: Flattish 2026 Revenue Growth Aside, Stock Still Looks A Buy (AMRX) - Seeking Alpha

Mar 16, 2026

Zacks Industry Outlook Highlights Terns Pharmaceuticals, ADMA Biologics, ANI Pharmaceuticals and Liquidia - TradingView

Mar 16, 2026

Ionis Pharmaceuticals, Inc. $IONS Shares Purchased by Jain Global LLC - MarketBeat

Mar 16, 2026